TCGA-BH-A204-01A-11R-A157-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 84
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.510
- PROTEIN_SECRETION+0.460
- MYC_TARGETS_V1+0.450
- G2M_CHECKPOINT+0.420
- UNFOLDED_PROTEIN_RESPONSE+0.270
- MTORC1_SIGNALING+0.220
- ANDROGEN_RESPONSE+0.190
- OXIDATIVE_PHOSPHORYLATION+0.190
- MITOTIC_SPINDLE+0.180
- UV_RESPONSE_DN+0.180
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.600
- ALLOGRAFT_REJECTION-0.490
- INTERFERON_GAMMA_RESPONSE-0.490
- IL6_JAK_STAT3_SIGNALING-0.450
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.400
- TNFA_SIGNALING_VIA_NFKB-0.390
- CHOLESTEROL_HOMEOSTASIS-0.360
- INFLAMMATORY_RESPONSE-0.350
- APICAL_SURFACE-0.330
- COAGULATION-0.330
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1797280 | — | cohortSC | 0.901 |
| 2 | TCGA-86-8054-01A-11R-2241-07 | — | cohortA3 | 0.899 |
| 3 | SRR3147744 | — | — | 0.889 |
| 4 | SJEPD030795_D2.RNA-Seq | EPN | Posterior Fossa EPN | 0.888 |
| 5 | TCGA-E9-A228-01A-31R-A157-07 | — | B | 0.885 |
| 6 | SRR33532819 | — | E | 0.885 |
| 7 | R375 | — | — | 0.879 |
| 8 | CA366342-0949-4941-8AE6-984BAF032886 | — | — | 0.872 |
| 9 | TCGA-AR-A24K-01A-11R-A169-07 | — | B | 0.869 |
| 10 | SRR5088922 | — | — | 0.866 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.510 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.460 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.450 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.420 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.270 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.220 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.190 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.190 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.180 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.180 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.170 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.160 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.160 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.110 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.090 | Temsirolimus | — uncovered |
| ANGIOGENESIS | 0.080 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.080 | Idelalisib | — uncovered |